Dublin, April 25, 2019 (GLOBE NEWSWIRE) -- The "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 12, 2 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Alpha- Antitrypsin Deficiency - Overview
  4. Alpha- Antitrypsin Deficiency - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Alpha- Antitrypsin Deficiency - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development
  • Adverum Biotechnologies Inc
  • Alnylam Pharmaceuticals Inc
  • Applied Genetic Technologies Corp
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Editas Medicine Inc
  • Grifols SA
  • Inhibrx LP
  • Intellia Therapeutics Inc
  • International Stem Cell Corp
  • Kamada Ltd
  • Logicbio Therapeutics Inc
  • OncBioMune Pharmaceuticals, Inc.
  • PlantForm Corp
  • Promethera Biosciences SA
  • ProMetic Life Sciences Inc
  • Santhera Pharmaceuticals Holding AG
  • Vertex Pharmaceuticals Inc
  • Z Factor Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gjolwz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs